Kwasi Ansere Ofori, MBChB, MPH
Postdoctoral AssociateAbout
Research
Publications
2026
Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma
Bader JM, Dhiman A, Aguirre N, Ofori KA, Gupta P, Qin H, Sharma A, Mitchell O, Tjota MY, Husain AN, Drazer M, Churpek J, Kindler H, Turaga K. Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma. Npj Precision Oncology 2026 DOI: 10.1038/s41698-026-01495-x.Peer-Reviewed Original ResearchThis study investigates the prognostic impact of somatic mutations in mesothelioma, showing NF2 truncating variants worsen survival, supporting genomic testing to guide treatment strategies.A Microvascular Risk Score Predicts Limb Outcomes After Infrainguinal Revascularization for Chronic Limb-threatening Ischemia: A Vascular Quality Initiative Analysis
Ofori K, Hashmi M, Kahn M, Boutrous M, Kariya C, Kull D, Amankwah K. A Microvascular Risk Score Predicts Limb Outcomes After Infrainguinal Revascularization for Chronic Limb-threatening Ischemia: A Vascular Quality Initiative Analysis. Journal Of Vascular Surgery 2026, 84: e23-e24. DOI: 10.1016/j.jvs.2026.03.478.Peer-Reviewed Original ResearchPeritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance
Ofori KA, Smart H, Liu S, Bader JM, Aguirre N, Gupta P, Sharma A, Turaga K. Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance. Annals Of Surgical Oncology 2026 DOI: 10.1245/s10434-026-19903-8.Peer-Reviewed Original ResearchThis study investigates the limitations of circulating tumor DNA (ctDNA) surveillance in stage II–III colon cancer, showing reduced detection of isolated peritoneal metastases due to biological constraints.Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance
Ofori K, Smart H, Liu S, Bader J, Aguirre N, Gupta P, Sharma A, Turaga K. Peritoneal Metastases in Stage II–III Colon Cancer Represent a Blind Spot for Circulating Tumor DNA Surveillance. Annals Of Surgical Oncology 2026, 1-4. PMID: 42265516, DOI: 10.1245/s10434-026-19903-8.Peer-Reviewed Original ResearchThis study investigates the limitations of circulating tumor DNA (ctDNA) surveillance in stage II–III colon cancer, showing reduced detection of isolated peritoneal metastases due to biological constraints.Associations of autoimmune diseases with appendiceal cancer in a population-based study.
Ofori K, Bader J, Reddy B, Aguirre N, Gupta P, Sharma A, Godfrey E, Ong C, Cecchini M, Sundar R, Turaga K. Associations of autoimmune diseases with appendiceal cancer in a population-based study. Journal Of Clinical Oncology 2026, 44: e16495-e16495. DOI: 10.1200/jco.2026.44.16_suppl.e16495.Peer-Reviewed Original Researchelectronic health recordspopulation-based studycancer-free controlshealth recordscausal pathwaysodds ratioUs Research Programsex-adjusted analysessex-adjusted modelstype 1 diabetesinflammatory bowel diseasep-valueno historyAdjusted ORcancer casesICD codesU.S. cohortrheumatoid arthritisadult participantslogistic regressionappendiceal cancerbenign thyroid disordersautoimmune thyroid diseasehighest prevalencethyroid disordersNew-onset inflammatory bowel disease associated with immune checkpoint inhibitor therapy: A real-world multicenter analysis.
Orhin A, Mensah B, Akoto N, Afrifa-Yamoah J, Ofori K, Burke O. New-onset inflammatory bowel disease associated with immune checkpoint inhibitor therapy: A real-world multicenter analysis. Journal Of Clinical Oncology 2026, 44: 11141-11141. DOI: 10.1200/jco.2026.44.16_suppl.11141.Peer-Reviewed Original Researchimmune checkpoint inhibitorsimmune checkpoint inhibitor exposureinflammatory bowel disease therapyinflammatory bowel diseaseincident inflammatory bowel diseasepropensity score matchinginitiation of first-line therapyhazard ratioimmune checkpoint inhibitor cohortimmune checkpoint inhibitor therapypatients treated with chemotherapyDe novo inflammatory bowel diseasechronic immune-mediated conditioncancer typesICI-treated patientsimmune checkpoint inhibitioncheckpoint inhibitor therapyCTLA-4 inhibitorsPD-1/PD-L1chemotherapy-treated patientsfirst-line therapyscore matchingKaplan-Meier analysisimmune-mediated conditionsretrospective cohort studyA familiar paradox in a new exposure: Electronic cigarettes and thyroid cancer.
Akoto N, Orhin A, Mensah B, Afrifa-Yamoah J, Burke O, Ofori K. A familiar paradox in a new exposure: Electronic cigarettes and thyroid cancer. Journal Of Clinical Oncology 2026, 44: e22601-e22601. DOI: 10.1200/jco.2026.44.16_suppl.e22601.Peer-Reviewed Original Researche-cigarette useassociated with lower oddscross-sectional analysiscombustible cigarette smokinge-cigarettescigarette smokinglower oddscross-sectional analysis of adultselectronic cigarettesrisk of thyroid cancerUs Research Programconfidence intervalsassociated with thyroid cancerthyroid cancerself-reported survey datalow riskbody mass indexmultivariate logistic regressionpopulation-based analysisanalysis of adultse-cigarette usersconventional cigarette smokingsmoking statusdiagnosis codesodds ratioTrends and disparities in cancer mortality among individuals with substance use disorder in the United States, 1999-2020.
Akoto N, Orhin A, Mensah B, Ofori K, Afrifa-Yamoah J, Burke O. Trends and disparities in cancer mortality among individuals with substance use disorder in the United States, 1999-2020. Journal Of Clinical Oncology 2026, 44: e22602-e22602. DOI: 10.1200/jco.2026.44.16_suppl.e22602.Peer-Reviewed Original Researchage-adjusted mortality ratesaverage annual percent changeannual percent changecancer mortalitysubstance use disorderscancer carehighest age-adjusted mortality ratepatterns of cancer mortalityuse disordernon-Hispanic Black individualspercent changeU.S. standard populationU.S. cancer mortalityconfidence intervalscontext of substance use disordersnon-Hispanic whitesAmerican Indian/Alaska Nativesubstance use servicesCDC WONDER databaseco-occurring substance use disorderssubstance-related conditionscross-sectional analysismortality ratemortality gapJoinpoint regressionClinical, Physiologic, and Anatomic Outcomes of a Novel Bioprosthetic Aortic Valved Conduit
Dankwa S, Erez E, Higaki A, Verma S, Hameed I, Talapaneni S, Wang K, Asmelash S, Oden Shobayo T, Khosla P, Ofori K, Assi R, Vallabhajosyula P. Clinical, Physiologic, and Anatomic Outcomes of a Novel Bioprosthetic Aortic Valved Conduit. Journal Of Clinical Medicine 2026, 15: 3437. PMID: 42123170, PMCID: PMC13163905, DOI: 10.3390/jcm15093437.Peer-Reviewed Original Researchaortic valved conduitcomputed tomographyConclusions:</b>functional outcomesMethods:</b>post-operative computed tomographyBio-Bentall procedureaortic root replacementearly hemodynamic performancelow mean gradientpost-operative mortalityLate Follow-upno survival differenceKaplan-Meier analysiseffective orifice areaanatomical outcomesroot replacementechocardiographic parameterspeak gradientcomplication ratebetween-group differencesretrospective studysurvival differencesvalved conduitsuperior hemodynamicsEvolving therapeutics in colorectal cancer peritoneal metastases
Bader J, Aguirre N, Schultz K, Ofori K, Godfrey E, Gupta P, Tseng R, Cecchini M, Sundar R, Turaga K. Evolving therapeutics in colorectal cancer peritoneal metastases. Cancer And Metastasis Reviews 2026, 45: 25. PMID: 42024175, DOI: 10.1007/s10555-026-10335-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptshyperthermic intraperitoneal chemotherapycolorectal cancer peritoneal metastasescytoreductive surgeryperitoneal metastasisclinical trialslandmark clinical trialsintraperitoneal chemotherapysystemic therapyCRC-PMtherapeutic challengediagnostic challengeguideline recommendationstherapeutic approachestreatment approachesmetastasistrialschemotherapysurgerytherapy
Get In Touch
Contacts
Email